Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group

Cancer Investigation

Volumn 22, Issue 6, 2004, Pages 832-839

  Gogas, Helen ^a   Bafaloukos, D ^b   Aravantinos, G ^c   Fountzilas, G ^d   Tsoutsos, D ^e   Panagiotou, P ^e   Frangia, K ^e   Kalofonos, H P ^f   Briasoulis, E ^g   Castana, O ^e   Polyzos, A ^a   Pectasides, D ^h   Ioannovich, J ^e  

^a UNIVERSITY OF ATHENS   (Greece)

^b Metropolitan Hospital   (Greece)

^c Agioi Anargiri Cancer Hospital   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e G GENNIMATAS GENERAL HOSPITAL   (Greece)

^f UNIVERSITY OF PATRAS   (Greece)

^g UNIVERSITY OF IOANNINA   (Greece)

^h METAXA CANCER HOSPITAL   (Greece)

Author keywords

Interleukin 2; Metastatic melanoma; Vinorelbine

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DOCETAXEL; INTERLEUKIN 2; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SEROTONIN ANTAGONIST; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INJECTION PAIN; LEUKOPENIA; MALE; MELANOMA; METASTASIS; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; SWEATING; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; SALVAGE THERAPY; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS; VINBLASTINE;

EID: 10844290954     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200039630     Document Type: Article

References (21)

1. Atkins, M.B. Management of stage IV melanoma. In ASCO Educational Book, 38th Annual Meeting, 2002; 175-183.
2. Rosenberg, S.A.; Yang, J.; Douglas, J.; Schwartzentruber, J.; Hwu, P.; Marincola, M.; Topalian, S.L.; Seipp, C.A.; Einborn, J.H.; White, D.E.; Stenberg, S.M. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon 2b. J. Clin. Oncol. 1999, 17, 968-975.
3. Keilholz, U.; Punt, C.J.A.; Gore, M.; Kruit, W.; Scheibenbogen, C.; Proebstle, Th.; Patel, P.; Lienard, D.; van Oosterom, A.; Eggermont, A.M.M. Dacarbazine, cisplatin and interferon alfa with or without interleukin-2 in advanced melanoma: interim analysis of EORTC Trial 18951. Proc. Am. Soc. Clin. Oncol. 1999, 18, 530a (abstract).
4. Eton, O.; Legha, S.S.; Bedikian, A.Y.; Lee, J.J.; Buzid, A.C.; Hodges, C.; Ring, S.E.; Papadopoulos, N.E.; Plager, C.; East, M.J.; Zhan, F.; Benjamin, R.S. Sequential biochemotherapy-versus chemotherapy for metastatic melanoma results from a phase III randomised trial. J. Clin. Oncol. 2002, 20, 2045-2052.
5. Bafaloukos, D.; Aravantinos, G.; Fountzilas, G.; Stathopoulos, G.; Gogas, H.; Samonis, G.; Briasoulis, E.; Mylonakis, N.; Skarlos, D.V.; Kosmidis, P. Docetaxel in combination with dacarbazine in patients with advanced melanoma. Oncology 2000, 63, 333-337.
6. Bafaloukos, D.; Gogas, H.; Georgoulias, V.; Briassoulis, E.; Fountzilas, G.; Samantas, E.; Kalofonos, Ch.; Skarlos, D.; Karabelis, A.; Kosmidis, P. Temozolomide in combination with docetaxel in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. J. Clin. Oncol. 2002, 20, 420-425.
7. Photiou, A.; Shah, P.; Leong, L.K.; Moss, J.; Retsas, S. In vitro synergy of paclitaxel (taxol) and vinorelbine (navelbine) against human melanoma cell line. Eur. J. Cancer 1997, 33, 463-470.
8. Photiou, A.; Sheikh, M.N.; Bafaloukos, D.; Retsas, S. Antiproliferative activity of vinorelbine (navel bine) against six human melanoma cell lines. J. Cancer Res. Clin. Oncol. 1992, 118, 249-254.
9. Retsas, S.; Mohith, A.; Mackenzie, H. Toxol and vinorelbine. A new active combination for disseminated malignant melanoma. Anti-cancer Drugs 1996, 7, 161-165.
10. Atkins, M.B.; Lotze, M.T.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.; Margolin, K.; Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; Paradise, C.; Kunkel, L.; Rosenber, S.A. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999, 17, 2105-2116.
11. Palmer, P.A.; Atzpodien, J.; Philip, T.; Negrier, S.; Kirchner, H.; Von der Maase, H.; Geertsen, P.; Evers, P.; Loriaux, E.; Oskam, R.; Roest, G.; Vinke, J.; Franks, C.R. A comparison of 2 modes of administration of recombinant interleukin 2: continous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal carcinoma. Cancer Biother. 1993, 8, 123-136.
12. Flaherty, L.A.; Atkins, M.; Sosman, J.; Weiss, G.; Clark, J.L.; Margolin, K.; Dutcher, J.; Gordon, M.S.; Lotze, M.; Mier, J.; Sorokin, P.; Fisher, R.I.; Appel, C.; Du, W. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J. Clin. Oncol. 2001, 19, 3194-3202.
13. Schmidt, H.; Geertsen, P.F.; Fode, K.; Rytter, C.; Bastholt, L.; von der Maase, H. Subcutaneous interleukin-2 and interferon-a plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma-a phase II study. Melanoma Res. 2000, 10, 66-77.
14. Middleton, M.R.; Grob, J.; Aaronson, N.; Fierlbeck, G.; Tilgen, W.; Seiter, S.; Gore, M.; Aamdal, S.; Cebon, J.; Coates, A.; Dreno, B.; Henz, M.; Schadendorf, D.; Kapp, A.; Weiss, J.; Fraass, U.; Statkevich, P.; Muller, M.; Thatcher, N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000, 18, 158-166.
15. Nathan, F.E.; Berd, D.; Sato, T.; Mastangelo, M.J. Paclitaxel and tamoxifen: an active regimen for patients with metastatic melanoma. Cancer 2000, 88, 79-87.
16. Falkson, C.I.; Ibrahim, J.; Kirkwood, J.M.; Goates, L.S.; Atkins, M.P.; Blum, P.H. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma. An Eastern Cooperative Oncology Group study. J. Clin. Oncol. 1998, 16, 1743-1751.
17. Chapman, P.B.; Einhorn, L.H.; Meyers, M.L.; Saxman, S.; Destro, A.N.; Panageas, K.S.; Begg, C.B.; Agarwala, S.S.; Schuchter, L.M.; Ernstoff, M.S.; Houghton; Kirkwood, J.M. Phase III multicenter randomized trial of the Darmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 1999, 17, 2745-2751.
18. Agarwala, S.S.; Glaspy, J.; O'Day, S.J.; Mitchell, M.; Gutheil, J.; Whitman, E.; Gonzalez, R.; Hersh, E.; Feun, L.; Belt, R.; Meyskens, F.; Hellstrand, K.; Wood, D.; Kirkwood, J.M.; Gehlsen, K.R.; Naredi, P. Results from a multicenter phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J. Clin. Oncol. 2002, 20, 125-133.
19. Phan, G.Q.; Attia, P.; Steinberg, S.M.; White, D.E.; Rosenberg, S.A. Factors associated with response to high dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 2001, 19, 3477-3482.
20. Chang, E.; Rosenberg, S.A. Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2 based therapy. J. Immunother. 2001, 24, 88-90.
21. Ridolfi, R.; Chiarion-Sileni, V.; Guida, M.; Romanini, A.; Labianca, R.; Freschi, A.; Lo Re Giovanni; Nortillli, R.; Brugnara, S.; Vitali, P.; Nanni, O. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J. Clin. Oncol. 2002, 20, 1600-1607.